Recursion Pharmaceuticals to update on FDA trial design for REC-4881 for FAP in the second half of 2026. Analysts expect potential upside from rare diseases.

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Sakana AI has opened a Recursive Self-Improvement Lab to test whether AI systems can help redesign and optimize future AI ...

Recursion Pharmaceuticals is trying to solve a serious problem. Even with technological improvements, the time and costs required to develop brand-new drugs have increased in recent decades. It can ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Recursion is building an industrialized engine for medicine. It operates among biotech stocks, selling access to its proprietary platform and pursuing joint development with major partners like Roche ...

Christopher Gibson, Co-Founder and CEO, announced, "beginning January 1, the amazing Najat Khan is going to take over the role of CEO, President and Director of Recursion." Gibson will transition to ...

CEO Jensen Huang reiterated what he has been saying out loud all this time, although this time his words were a little bit ...

Algorithms give computers step-by-step instructions to complete tasks accurately.Good algorithms improve software speed, ...

“But full recursive self-improvement also might increase the risks of humans losing control over AI systems,” it warns adding “If systems are capable of fully building their own successors, the ways ...